740 related articles for article (PubMed ID: 25755769)
1. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
3. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
4. Immunoprofile-based subgrouping of urothelial bladder carcinomas for survival prediction.
Kim K; Sung CO; Park BH; Ku JY; Go H; Ro JY; Kim J; Cho YM
Hum Pathol; 2015 Oct; 46(10):1464-70. PubMed ID: 26232864
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
7. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
[TBL] [Abstract][Full Text] [Related]
10. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
[TBL] [Abstract][Full Text] [Related]
11. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
12. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
[TBL] [Abstract][Full Text] [Related]
13. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.
Ge P; Wang ZC; Yu X; Lin J; He Q
BMC Urol; 2015 May; 15():46. PubMed ID: 26025446
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
20. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.
Kim KH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Urol Oncol; 2013 Nov; 31(8):1643-9. PubMed ID: 22591745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
